Demographics at baseline and history of Parkinson’s disease
| Fluctuating patients (n=172) | Non-fluctuating patients (n=128) | |||
|---|---|---|---|---|
| Variable | Entacapone (n=115) | Placebo (n=57) | Entacapone (n=88) | Placebo (n=40) |
| Values are mean (SD) or n (%). | ||||
| *UPDRS, question 32. | ||||
| CR, controlled release; PD, Parkinson’s disease. | ||||
| Sex (n (%)) | ||||
| Male | 69 (60.0%) | 40 (70.2%) | 63 (71.6%) | 28 (70.0%) |
| Female | 46 (40.0%) | 17 (29.8%) | 25 (28.4%) | 12 (30.0%) |
| Age (years) | 65.9 (8.9) | 64.7 (8.5) | 67.8 (9.4) | 68.1 (8.9) |
| Weight (kg) | 68.4 (14.3) | 70.3 (13.6) | 73.9 (14.7) | 75.7 (12.1) |
| Age at onset of PD (years) | 56.9 (10.3) | 56.2 (9.0) | 62.9 (11.0) | 63.1 (9.0) |
| Duration of PD (years) | 9.6 (5.1) | 9.1 (5.3) | 5.4 (4.8) | 5.6 (4.6) |
| Occurrence of dyskinesias* (n (%)) | 60 (54.4%) | 38 (71.7%) | 11 (12.6%) | 8 (21.1%) |
| Duration of levodopa treatment (years) | 8.1 (4.6) | 7.7 (4.9) | 3.7 (3.9) | 3.8 (3.8) |
| Daily levodopa dose (mg) | 682 (390) | 712 (369) | 500 (259) | 524 (335) |
| Standard levodopa only (n (%)) | 46 (40.7%) | 29 (53.7%) | 43 (51.8%) | 29 (72.5%) |
| CR levodopa only (n (%)) | 31 (27.4%) | 12 (22.2%) | 17 (20.5%) | 4 (10.0%) |
| Standard and CR levodopa (n (%)) | 36 (31.9%) | 13 (24.1%) | 23 (27.7%) | 7 (17.5%) |
| Other antiparkinsonian drugs (n (%)) | 77 (67.0%) | 41 (71.9%) | 28 (31.8%) | 14 (35.0%) |
| Dopamine agonists | 46 (40.0%) | 20 (35.1%) | 8 (9.1%) | 8 (20.0%) |
| Selegiline | 38 (33.0%) | 26 (45.6%) | 16 (18.2%) | 4 (10.0%) |
| Anticholinergics | 16 (14.0%) | 10 (17.6%) | 5 (5.7%) | 6 (15.0%) |
| Amantadine | 4 (3.5) | − | 4 (4.5%) | 1 (2.5%) |